Zang X: 2018 nobel prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade-A personal account. Genes Dis. 5:302–303. 2018. View Article : Google Scholar : PubMed/NCBI

Xie R, Shang B, Bi X, Cao C, Guan Y, Shi H and Shou J: Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis. Cancer Innov. 1:293–304. 2022. View Article : Google Scholar : PubMed/NCBI

Seidel JA, Otsuka A and Kabashima K: Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol. 8:862018. View Article : Google Scholar

Li H, Yuan S, Wu H, Wang Y, Ma Y, Tang X, Fu X, Zhao L, Xu B, Li T, et al: Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer. Cancer Innov. 3:e1552024. View Article : Google Scholar : PubMed/NCBI

Zhao J, Zhuo X, Liu L, Yang Z and Fu G: Opportunities and challenges of immune checkpoint inhibitors for extensive-stage small-cell lung cancer. Cancer Innov. 1:183–193. 2022. View Article : Google Scholar : PubMed/NCBI

Mao L, Yang M, Fan X, Li W, Huang X, He W, Lin T and Huang J: PD-1/L1 inhibitors can improve but not replace chemotherapy for advanced urothelial carcinoma: A systematic review and network meta-analysis. Cancer Innov. 2:191–202. 2023. View Article : Google Scholar : PubMed/NCBI

Rudd CE, Taylor A and Schneider H: CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 229:12–26. 2009. View Article : Google Scholar : PubMed/NCBI

Rowshanravan B, Halliday N and Sansom DM: CTLA-4: A moving target in immunotherapy. Blood. 131:58–67. 2018. View Article : Google Scholar : PubMed/NCBI

Kim GR and Choi JM: Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy. Mol Cells. 45:513–521. 2022. View Article : Google Scholar : PubMed/NCBI

Babamohamadi M, Mohammadi N, Faryadi E, Haddadi M, Merati A, Ghobadinezhad F, Amirian R, Izadi Z and Hadjati J: Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death Dis. 15:172024. View Article : Google Scholar : PubMed/NCBI

Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM and Reck M: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 30:2046–2054. 2012. View Article : Google Scholar

Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM and Laheru DA: Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 36:382–389. 2013. View Article : Google Scholar : PubMed/NCBI

Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K and Kulasinghe A: Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 29:3044–3060. 2022. View Article : Google Scholar

Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Stanisavljevic D, Dugalic MG, Sengul D, Detanac DA, Sengul I, et al: Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy. Clinics (Sao Paulo). 78:1001772023. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Zhang Y, Liu C, Shao J, Chen Y, Zhu Y, Zhang L, Qin B, Kong Z, Wang X, et al: A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer. Cancer Innov. 2:172–180. 2023. View Article : Google Scholar : PubMed/NCBI

Sun D, Xing P and Li J: PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cells. Cancer Innov. 1:348–349. 2022. View Article : Google Scholar : PubMed/NCBI

Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 13:9644422022. View Article : Google Scholar

Han Y, Liu D and Li L: PD-1/PD-L1 pathway: Current researches in cancer. Am J Cancer Res. 10:727–742. 2020.PubMed/NCBI

Ai L, Xu A and Xu J: Roles of PD-1/PD-L1 pathway: Signaling, cancer, and beyond. Adv Exp Med Biol. 1248:33–59. 2020. View Article : Google Scholar

Topalian SL, Drake CG and Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar

Chikuma S: Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol. 21:448–455. 2016. View Article : Google Scholar

Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu K: Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI

De Velasco MA, Kura Y, Fujita K and Uemura H: Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer. Int J Urol. 31:307–324. 2024. View Article : Google Scholar

Xue J, Liu C, Shao J, Wang L, Han Y and Wang J and Wang J: Predictive value of neutrophil-to-lymphocyte ratio for immune checkpoint inhibitor-related myocarditis among patients treated for non-small-cell lung cancer. Cancer Innov. 4:e1632025. View Article : Google Scholar : PubMed/NCBI

Postow MA, Sidlow R and Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI

Tucker L, Sacks S and Al-Mossawi H: THU0562 Inflammatory joint disease triggered by immune checkpoint inhibitors. Ann Rheum Dis. 76:4192017. View Article : Google Scholar

Lee DJ, Lee HJ Jr, Farmer JR and Reynolds KL: Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Cardiol Rep. 23:982021. View Article : Google Scholar : PubMed/NCBI

Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M and Reynolds KL: Immune-related adverse events (irAEs): Diagnosis, management, and clinical Pearls. Curr Oncol Rep. 22:392020. View Article : Google Scholar : PubMed/NCBI

Melia A, Fockens E, Sfumato P, Zemmour C, Madroszyk A, Lafforgue P and Pham T: Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. Joint Bone Spine. 90:1054572023. View Article : Google Scholar : PubMed/NCBI

Thapa B, Roopkumar J, Kim AS, Gervaso L, Patil PD, Calabrese C, Khorana AA and Funchain P: Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI). J Clin Oncol. 37:e141512019. View Article : Google Scholar

Jeurling S and Cappelli LC: Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Curr Opin Rheumatol. 32:315–320. 2020. View Article : Google Scholar

Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J and Jordan K; ESMO Guidelines Committee, : Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (Suppl 4):iv119–iv142. 2017. View Article : Google Scholar

Chan KK and Bass AR: Monitoring and management of the patient with immune checkpoint inhibitor-induced inflammatory arthritis: Current perspectives. J Inflamm Res. 15:3105–3118. 2022. View Article : Google Scholar : PubMed/NCBI

Calabrese C, Kirchner E, Kontzias A, Velcheti V and Calabrese LH: Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity. RMD Open. 3:e0004122017. View Article : Google Scholar : PubMed/NCBI

Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, et al: Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 76:43–50. 2017. View Article : Google Scholar : PubMed/NCBI

Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M and Diab A: Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: A case series. Ann Rheum Dis. 76:2061–2064. 2017. View Article : Google Scholar : PubMed/NCBI

Abe K, Ishikawa Y, Fujiwara M, Yukawa H, Yanagihara T, Takei S, Arioka H and Kita Y: Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report. Medicine (Baltimore). 101:e284282022. View Article : Google Scholar : PubMed/NCBI

Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak TW and Ohashi PS: TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest. 117:3833–3845. 2007. View Article : Google Scholar

Chang Q, Daly L and Bromberg J: The IL-6 feed-forward loop: A driver of tumorigenesis. Semin Immunol. 26:48–53. 2014. View Article : Google Scholar

Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, Oike Y, Endo M, Ibusuki M, Hiraki A, et al: Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 15:5426–5434. 2009. View Article : Google Scholar : PubMed/NCBI

U.S. Department of Health and Human Services, . Common terminology criteria for adverse events (CTCAE) version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5×7.pdfOctober 31–2019

Albayda J, Dein E, Shah AA, Bingham CO III and Cappelli L: Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: A case series. ACR Open Rheumatol. 1:303–307. 2019. View Article : Google Scholar

Smith MH and Bass AR: Arthritis after cancer immunotherapy: Symptom duration and treatment response. Arthritis Care Res (Hoboken). 71:362–366. 2019. View Article : Google Scholar : PubMed/NCBI

Cappelli LC, Gutierrez AK, Bingham CO III and Shah AA: Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care Res (Hoboken). 69:1751–1763. 2017. View Article : Google Scholar : PubMed/NCBI

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, et al: Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study. Ann Rheum Dis. 77:393–398. 2018. View Article : Google Scholar : PubMed/NCBI

Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz HM and Hassel JC: Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 67:175–182. 2018. View Article : Google Scholar : PubMed/NCBI

Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R and Markel G: Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 17:284–289. 2018. View Article : Google Scholar : PubMed/NCBI

Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A and Buttgereit F: Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 68:1119–1124. 2009. View Article : Google Scholar : PubMed/NCBI

Damuzzo V, Solito S, Pinton L, Carrozzo E, Valpione S, Pigozzo J, Giancristofaro RA, Chiarion-Sileni V and Mandruzzato S: Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology. 5:e12495592016. View Article : Google Scholar : PubMed/NCBI

Tachibana H, Nemoto Y, Ishihara H, Fukuda H, Yoshida K, Iizuka J, Hashimoto Y, Kondo T, Tanabe K and Takagi T: Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer. 20:e81–e88. 2022. View Article : Google Scholar : PubMed/NCBI

Shi Y, Liu X, Du J, Zhang D, Liu J, Chen M, Zhao J, Zhong W, Xu Y and Wang M: Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. Thorac Cancer. 13:219–227. 2022. View Article : Google Scholar : PubMed/NCBI

Diehl S and Rincón M: The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 39:531–536. 2002. View Article : Google Scholar

Vilgelm AE: Illuminating the mechanism of IL-6-mediated immunotherapy resistance. Cell Rep Med. 4:1009012023. View Article : Google Scholar : PubMed/NCBI

Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y and Oshiumi H: Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 78:5011–5022. 2018. View Article : Google Scholar : PubMed/NCBI

Kishimoto T: The biology of interleukin-6. Blood. 74:1–10. 1989. View Article : Google Scholar : PubMed/NCBI

Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K and Iwamatsu A: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 324:73–76. 1986. View Article : Google Scholar : PubMed/NCBI

Tanaka T and Kishimoto T: The biology and medical implications of interleukin-6. Cancer Immunol Res. 2:288–294. 2014. View Article : Google Scholar : PubMed/NCBI

Tanaka T, Narazaki M and Kishimoto T: IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 6:a0162952014. View Article : Google Scholar

Hirano T: IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 33:127–148. 2021. View Article : Google Scholar

Dienz O and Rincon M: The effects of IL-6 on CD4 T cell responses. Clin Immunol. 130:27–33. 2009. View Article : Google Scholar

Kimura A and Kishimoto T: IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 40:1830–1835. 2010. View Article : Google Scholar

Tanaka T, Narazaki M and Kishimoto T: Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 52:199–219. 2012. View Article : Google Scholar

Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T and Naka T: Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 52:3264–3271. 2011. View Article : Google Scholar

Ma CS, Deenick EK, Batten M and Tangye SG: The origins, function, and regulation of T follicular helper cells. J Exp Med. 209:1241–1253. 2012. View Article : Google Scholar : PubMed/NCBI

Feng W, Liu H, Luo T, Liu D, Du J, Sun J, Wang W, Han X, Yang K, Guo J, et al: Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways. Sci Rep. 7:414112017. View Article : Google Scholar : PubMed/NCBI

Akira S, Taga T and Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol. 54:1–78. 1993. View Article : Google Scholar

Rose-John S: Interleukin-6 signalling in health and disease. F1000Res. 9:F1000Faculty Rev. –1013. 2020. View Article : Google Scholar : PubMed/NCBI

Groza Y, Jemelkova J, Kafkova LR, Maly P and Raska M: IL-6 and its role in IgA nephropathy development. Cytokine Growth Factor Rev. 66:1–14. 2022. View Article : Google Scholar : PubMed/NCBI

Hunter CA and Jones SA: IL-6 as a keystone cytokine in health and disease. Nat Immunol. 16:448–457. 2015. View Article : Google Scholar

Wang J, Sun Q, Zhang J, Wang H and Liu H: Classical signaling and trans-signaling pathways stimulated by megalobrama amblycephala IL-6 and IL-6R. Int J Mol Sci. 23:20192022. View Article : Google Scholar

Schmidt-Arras D and Rose-John S: Endosomes as signaling platforms for IL-6 family cytokine receptors. Front Cell Dev Biol. 9:6883142021. View Article : Google Scholar

Rose-John S: IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 8:1237–1247. 2012. View Article : Google Scholar

Song M, Wang Y, Annex BH and Popel AS: Experiment-based computational model predicts that IL-6 classic and trans-signaling exhibit similar potency in inducing downstream signaling in endothelial cells. NPJ Syst Biol Appl. 9:452023. View Article : Google Scholar

Kozłowski L, Zakrzewska I, Tokajuk P and Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 48:82–84. 2003.

Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa E, Sugawara Y, Akechi T, Wada N, Imoto S, Murakami K, et al: Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy. Cancer Med. 3:702–709. 2014. View Article : Google Scholar : PubMed/NCBI

Mori S, Murakami-Mori K and Bonavida B: Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun. 257:609–614. 1999. View Article : Google Scholar : PubMed/NCBI

Klausen P, Pedersen L, Jurlander J and Baumann H: Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 19:3675–3683. 2000. View Article : Google Scholar : PubMed/NCBI

Moran DM, Mattocks MA, Cahill PA, Koniaris LG and McKillop IH: Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res. 147:23–33. 2008. View Article : Google Scholar : PubMed/NCBI

Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM and Kerbel RS: Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene. 18:1023–1032. 1999. View Article : Google Scholar

Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmüller U, Nakajima K, Hirano T, Horn F and Behrmann I: Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 18:3742–3753. 1999. View Article : Google Scholar : PubMed/NCBI

Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M and Jadidi-Niaragh F: The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother. 108:1415–1424. 2018. View Article : Google Scholar : PubMed/NCBI

Cathcart JM, Banach A, Liu A, Chen J, Goligorsky M and Cao J: Interleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression. Oncotarget. 7:61107–61120. 2016. View Article : Google Scholar

Chung YC, Chen SJ, Huang CC, Liu WC, Lai MT, Kao TY, Yang WS, Yang CH, Hsu CP and Chang JF: Tocilizumab exerts anti-tumor effects on colorectal carcinoma cell xenografts corresponding to expression levels of interleukin-6 receptor. Pharmaceuticals (Basel). 17:1272024. View Article : Google Scholar : PubMed/NCBI

Chonov DC, Ignatova MMK, Ananiev JR and Gulubova MV: IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Med Sci. 7:2391–2398. 2019. View Article : Google Scholar

Fu C, Jiang L, Hao S, Liu Z, Ding S, Zhang W, Yang X and Li S: Activation of the IL-4/STAT6 signaling pathway promotes lung cancer progression by increasing M2 myeloid cells. Front Immunol. 10:26382019. View Article : Google Scholar

Huang B, Lang X and Li X: The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol. 12:10231772022. View Article : Google Scholar

Xu J, Lin H, Wu G, Zhu M and Li M: IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol. 11:7609712021. View Article : Google Scholar

Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K and Takahashi K: Tocilizumab, a proposed therapy for the cachexia of interleukin6-expressing lung cancer. PLoS One. 9:e1024362014. View Article : Google Scholar : PubMed/NCBI

Bayliss TJ, Smith JT, Schuster M, Dragnev KH and Rigas JR: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 11:1663–1668. 2011. View Article : Google Scholar : PubMed/NCBI

Fa'ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH, et al: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer. 11:e0068142023. View Article : Google Scholar

Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014. View Article : Google Scholar : PubMed/NCBI

Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M and Takeyama H: Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer. 110:469–478. 2014. View Article : Google Scholar : PubMed/NCBI

Oguro T, Ishibashi K, Sugino T, Hashimoto K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T, et al: Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression. Eur J Cancer. 49:1715–1724. 2013. View Article : Google Scholar : PubMed/NCBI

Wang D, Xu J, Liu B, He X, Zhou L, Hu X, Qiao F, Zhang A, Xu X, Zhang H, et al: IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer. Cell Death Differ. 25:330–339. 2018. View Article : Google Scholar : PubMed/NCBI

Holmstroem RB, Nielsen OH, Jacobsen S, Riis LB, Theile S, Bjerrum JT, Vilmann P, Johansen JS, Boisen MK, Eefsen RHL, et al: COLAR: Open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J Immunother Cancer. 10:e0051112022. View Article : Google Scholar : PubMed/NCBI

Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN and Thanarajasingam U: Rheumatic syndromes associated with immune checkpoint inhibitors: A single-center cohort of sixty-one patients. Arthritis Rheumatol. 71:468–475. 2019. View Article : Google Scholar

Abdel-Wahab N, Shah M, Lopez-Olivo MA and Suarez-Almazor ME: Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann Intern Med. 168:121–130. 2018. View Article : Google Scholar : PubMed/NCBI

Mooradian M, Fintelmann F, Fadden R, Rubin KM, Lawless A, Vitali M, Sharova T, Boland GM, Lawrence DP, Cohen JV, et al: A phase II study of cryoablation (cryo) of an enlarging tumor in patients (pts) with advanced lung cancer or melanoma receiving post-progression immune checkpoint inhibition (ICI). J Clin Oncol. 37:e14243. 2019. View Article : Google Scholar

Verspohl SH, Holderried T, Behning C, Brossart P and Schäfer VS: Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: A single-centre analysis. Ther Adv Musculoskelet Dis. 13:1759720×2110069632021. View Article : Google Scholar

Ladouceur A, Barnetche T, Mouterde G, Tison A, Bitoun S, Prey S, Dutriaux C, Gerard E, Pham-Ledard A, Beylot-Barry M, et al: Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: A multicentre observational study. RMD Open. 9:e0037952023. View Article : Google Scholar : PubMed/NCBI

Pirker I, Rubbert-Roth A, von Kempis J, Fehr M and Neumann T: Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy. Clin Exp Rheumatol. 38:573–574. 2020.

Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ, Sullivan RJ and Schoenfeld SR: Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Semin Arthritis Rheum. 48:1127–1132. 2019. View Article : Google Scholar : PubMed/NCBI

Liapi M and Chatzidionysiou K: POS1356 treatment of immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica. Ann Rheum Dis. 81:10172022. View Article : Google Scholar : PubMed/NCBI

Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, et al: Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 3:4228–4237. 2019. View Article : Google Scholar : PubMed/NCBI

Hu X, Li J, Fu M, Zhao X and Wang W: The JAK/STAT signaling pathway: From bench to clinic. Signal Transduct Target Ther. 6:4022021. View Article : Google Scholar : PubMed/NCBI

Byer SH, Stewart C, Mansour S and Grewal US: Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune checkpoint blockade-induced myocarditis with myasthenia and myositis overlap syndrome. Eur J Cancer. 202:1140272024. View Article : Google Scholar : PubMed/NCBI

Schust J, Sperl B, Hollis A, Mayer TU and Berg T: Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar

Yue P and Turkson J: Targeting STAT3 in cancer: How successful are we? Expert Opin Investig Drugs. 18:45–56. 2009. View Article : Google Scholar : PubMed/NCBI

Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang Z and Wang X: The diverse function of PD-1/PD-l pathway beyond cancer. Front Immunol. 10:22982019. View Article : Google Scholar

Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, Klareskog L, Catrina AI, Sidiropoulos P and Boumpas DT: The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 62:1870–1880. 2010. View Article : Google Scholar : PubMed/NCBI

Kong EKP, Prokunina-Olsson L, Wong WHS, Lau CS, Chan TM, Alarcón-Riquelme M and Lau YL: A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum. 52:1058–1062. 2005. View Article : Google Scholar : PubMed/NCBI

Bommarito D, Hall C, Taams LS and Corrigall VM: Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol. 188:455–466. 2017. View Article : Google Scholar

Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu LF, Li Y, Gupta V, Li C, et al: CD8⁺T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 4:1008782023. View Article : Google Scholar : PubMed/NCBI

Yu Y, Wang S, Su N, Pan S, Tu B, Zhao J, Shen Y, Qiu Q, Liu X, Luan J, et al: Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer. Front Oncol. 12:9068242022. View Article : Google Scholar

McArthur GA and Ribas A: Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol. 31:499–506. 2013. View Article : Google Scholar

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B and von Bergwelt-Baildon MS: Cytokine release syndrome. J Immunother Cancer. 6:562018. View Article : Google Scholar : PubMed/NCBI

Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, Ahmadian MR, Moll JM and Scheller J: The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. 293:6762–6775. 2018. View Article : Google Scholar : PubMed/NCBI

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI

Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, et al: Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 40:509–523.e506. 2022. View Article : Google Scholar

Mihara M, Ohsugi Y and Kishimoto T: Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. Open Access Rheumatol. 3:19–29. 2011. View Article : Google Scholar

Bystrom J, Taher TE, Henson SM, Gould DJ and Mageed RA: Metabolic requirements of Th17 cells and of B cells: Regulation and defects in health and in inflammatory diseases. Front Immunol. 13:9907942022. View Article : Google Scholar

Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J and Zhang L: B cells in rheumatoid arthritis: Pathogenic mechanisms and treatment prospects. Front Immunol. 12:7507532021. View Article : Google Scholar